Back to markets

Skin cancer vaccine BLA submitted by June 30, 2027?

Active · Ends Jul 1, 2027

Yes probability

75.5%

24h change

-1.00%

Total volume

$71,611

Liquidity

$3,600

Price history

YesNo
0%25%50%75%100%Oct 26Oct 30Nov 275.5%24.5%

Outcomes

Yes75.5%
No24.5%

Order book

Yes · 32 levels
BidsSize
  1. 75¢543
  2. 74¢1,464
  3. 73¢579
  4. 72¢161
  5. 68¢10
  6. 67¢10
  7. 66¢15
  8. 55¢30
AsksSize
  1. 76¢964
  2. 77¢2,161
  3. 78¢1,493
  4. 79¢272
  5. 83¢41
  6. 84¢44
  7. 85¢134
  8. 86¢400

No comments on this market yet.

Rules

This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.

Market opened Aug 19, 2026, 6:46 PM · Last updated Nov 2, 2026, 10:16 PM

Market data

24h volume

$205

1 week volume

$245

1 month volume

$23,197

1 year volume

$71,611

Spread

1.00%

Min order

5

Tick size

0.01

Competitiveness

93.9%

1h change

—

1 week change

-1.00%

1 month change

-7.00%

Negative risk

No

Condition ID:
0x5801ce623a1d2dcb20bec5708fd9f881326aaf1ff82af22248aceccc7bf29708
Question ID:
0x87a13762c467dae44def7cf035ecb289f6b9443cf7aec9bea754f57ab65d439d

Frequently asked questions

What is the "Skin cancer vaccine BLA submitted by June 30, 2027?" prediction market?

This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.

What are the current odds?

Yes at 75.5%, No at 24.5% Odds move with trading and refresh as the market updates.

How much trading activity has this market generated?

$71,611 in total volume, with $205 in the last 24 hours and $3,600 of liquidity currently available.

When does this market close?

Trading runs until Jul 1, 2027. The market opened on Aug 19, 2026.

How do I trade this market?

Holdytic is a read-only view of Polymarket data. Use the “Trade on Polymarket” link to place an order on Polymarket itself, where you can connect a wallet and fund a position.